We have previously shown that
laminin-8, a vascular basement membrane component, was overexpressed in human
glioblastomas multiforme and their adjacent tissues compared to normal brain. Increased
laminin-8 correlated with shorter
glioblastoma recurrence time and poor patient survival making it a potential marker for
glioblastoma diagnostics and prediction of disease outcome. However,
laminin-8 therapeutic potential was unknown because the technology of blocking the expression of multi-chain complex
proteins was not yet developed. To inhibit the expression of
laminin-8 constituents in
glioblastoma in vitro and in vivo, we used
Polycefin, a bioconjugate drug delivery system based on slime-mold Physarum polycephalum-derived
poly(malic acid). It carries an attached
transferrin receptor antibody to target
tumor cells and to deliver two conjugated
morpholino antisense oligonucleotides against
laminin-8 alpha4 and beta1 chains.
Polycefin efficiently inhibited the expression of both
laminin-8 chains by cultured
glioblastoma cells. Intracranial
Polycefin treatment of human U87MG
glioblastoma-bearing nude rats reduced incorporation of both
tumor-derived
laminin-8 chains into vascular basement membranes.
Polycefin was thus able to simultaneously inhibit the expression of two different chains of a complex
protein. The treatment also significantly reduced
tumor microvessel density (p < 0.001) and area (p < 0.001) and increased animal survival (p < 0.0004). These data suggest that
laminin-8 may be important for
glioblastoma angiogenesis.
Polycefin, a versatile nanoscale drug delivery system, was suitable for in vivo delivery of two
antisense oligonucleotides to
brain tumor cells causing a reduction of
glioblastoma angiogenesis and an increase of animal survival. This system may hold promise for future clinical applications.